Stock GPCR STRUCTURE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Structure Therapeutics Inc.

Equities

GPCR

US86366E1064

Market Closed - Nasdaq
Other stock markets
 01:30:00 24/05/2024 am IST 		5-day change 1st Jan Change
38.32 USD +5.33% Intraday chart for Structure Therapeutics Inc. +6.80% -5.99%
21/05 JPMorgan Starts Structure Therapeutics With Overweight Rating MT
09/05 Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Structure Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

b15a05d4.5_sdiUFn1dQld88EhUJY3nnVx6sRcQH6-7SAo01KQxg.gpJevQArgrkdMKU91Cgz6j2vtOdcITC4ycTu0H8-GV2zn2zueF6P42w2uA~6c207230f10835e62744e4a3606892e3

Analyst Recommendations on Structure Therapeutics Inc.

JPMorgan Starts Structure Therapeutics With Overweight Rating MT
Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target MT
JMP Securities Adjusts Structure Therapeutics' Price Target to $91 From $90, Keeps Market Outperform Rating MT
Piper Sandler Raises Price Target on Structure Therapeutics to $93 From $58, Maintains Overweight Rating MT
JMP Securities Starts Coverage on Structure Therapeutics with Market Outperform Rating, $90 Price Target MT
BMO Capital Adjusts Structure Therapeutics Price Target to $83 From $40, Maintains Outperform Rating MT
Piper Sandler Initiates Structure Therapeutics With Overweight Rating, $58 Price Target MT
SVB Securities Initiates Structure Therapeutics at Outperform Rating With $33 Price Target MT
BMO Capital Initiates Structure Therapeutics at Outperform With $40 Price Target MT
Jefferies Initiates Structure Therapeutics at Buy With $34 Price Target MT
Guggenheim Starts Structure Therapeutics at Buy With $50 Price Target MT
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
38.32 USD
Average target price
75.7 USD
Spread / Average Target
+97.55%
High Price Target
93 USD
Spread / Highest target
+142.69%
Low Price Target
48 USD
Spread / Lowest Target
+25.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Structure Therapeutics Inc.

JPMorgan Chase
Cantor Fitzgerald
JMP Securities
Piper Sandler
BMO Capital
Guggenheim
Jefferies & Co.
SVB Securities LLC

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GPCR Stock
  4. Consensus Structure Therapeutics Inc.